Cerebrolysin is a prescription neuropeptide preparation derived from pig brain tissue, primarily used in Eastern Europe and parts of Asia to treat stroke, traumatic brain injury (TBI), and dementia. It acts as a neuroprotective and neurotrophic agent, intended to support brain recovery and repair. 

Uses and Indications

Cerebrolysin is most commonly prescribed for:

• Acute Ischemic Stroke: Used to help minimize infarction size and improve neurological and motor recovery.

• Traumatic Brain Injury (TBI): Administered to support cognitive recovery and alleviate emotional impairments like anxiety and depression post-injury.

• Dementia: Prescribed to help manage cognitive symptoms associated with vascular dementia and Alzheimer's disease.

  
  

Administration

The medication is administered exclusively via injection or intravenous (IV) infusion by healthcare professionals. It is typically given in multi-day cycles (e.g., once daily for 5 days a week) over a period of several weeks, depending on the severity of the condition.

Availability and Regulation

Cerebrolysin is not approved by the FDA for use in the United States. Its availability is limited to countries where it is approved by local regulatory bodies, such as in the EU and Asia.

Safety Profile

While clinical studies suggest that Cerebrolysin is generally well-tolerated, potential side effects can include headache, dizziness, and mild gastrointestinal upset. Because it is derived from porcine (pig) proteins, it can theoretically carry a risk of allergic reactions and should be avoided by individuals with a history of hypersensitivity to its components. 

This is for informational purposes only. For medical advice or diagnosis, consult a professional.

This product for research use only.